Glatiramer Acetate in the Reduction of Relapse Frequency in Multiple Sclerosis

被引：0
|
作者：
Miravalle, Augusto [2 ]
Hendin, Barry [3 ]
Vollmer, Timothy L. [2 ]
Kala, Mrinalini [1 ,3 ]
机构：
[1] St Josephs Hosp, Barrow Neurol Inst, Div Neurol, 350 West Thomas Rd, Phoenix, AZ 85013 USA
[2] Univ Colorado Hlth Sci, Dept Neurol, Aurora, CO 80045 USA
[3] Univ Arizona, Coll Med, Phoenix, AZ USA
来源：
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS | 2011年 / 3卷
关键词：
multiple sclerosis; glatiramer acetate; relapse rate;
D O I：
10.4137/CMT.S2057
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Glatiramer acetate (GA; Copaxone (R)) is a heterogeneous polymer of four amino acids. It is one of the therapies approved by the Food and Drug Administration in 1996 for treatment of relapsing remitting multiple sclerosis (RRMS). GA reduces the relapse rate for RRMS, and has a good safety profile and moderate efficacy. Preclinical and clinical studies reveal that GA plays a role in modulating the cells of the immune system as well as in neuroprotection. In this article, we review the role of GA in reducing the frequency of relapses in MS, as well as its efficacy, safety, and current place in therapy.
引用
收藏
页码：151 / 158
页数：8
相关论文
共 50 条
  • [1] Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
    Fernandez, Oscar
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2012, 4 : 117 - 133
  • [2] JNK As a Biomarker of Relapse and Response to Treatment with Glatiramer Acetate in Multiple Sclerosis
    Anselmo, Freidrich
    Tatomir, Alexandru
    Ciriello, Jonathan
    Rus, Horea
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 26 - 26
  • [3] Is there risk of multiple sclerosis relapse with concomitant use of glatiramer acetate and antihistamines?
    Oleen-Burkey, M.
    Ollendorf, D.
    Castelli-Haley, J.
    MULTIPLE SCLEROSIS, 2007, 13 : S69 - S69
  • [4] Glatiramer acetate for multiple sclerosis
    La Mantia, Loredana
    Munari, Luca M.
    Lovati, Roberta
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (05):
  • [5] Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetate
    Greenberg, Benjamin
    Hall, Steven
    Grabner, Michael
    Balu, Sanjeev
    Zhang, Xian
    Kantor, Daniel
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (07) : 1167 - 1175
  • [6] Glatiramer acetate in multiple sclerosis: A review
    Ruggieri, Maddalena
    Avolio, Carlo
    Livrea, Paolo
    Trojano, Maria
    CNS DRUG REVIEWS, 2007, 13 (02): : 178 - 191
  • [7] Glatiramer acetate in the treatment of multiple sclerosis
    Miller, AE
    NEUROLOGIC CLINICS, 2005, 23 (01) : 215 - +
  • [8] Glatiramer acetate for relapsing multiple sclerosis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1997, 39 (1004): : 61 - 62
  • [9] Glatiramer acetate for the treatment of multiple sclerosis
    Wolinsky, JS
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (04) : 875 - 891
  • [10] Reduction of free radicals in multiple sclerosis:: effect of glatiramer acetate (Copaxone®)
    Iarlori, C.
    Gambi, D.
    Lugaresi, A.
    Patruno, A.
    Felaco, M.
    Salvatore, M.
    Speranza, L.
    Reale, M.
    MULTIPLE SCLEROSIS, 2008, 14 (06): : 739 - 748
12345